The Sero-Prevalence of HIV-1 among Visceral Leishmaniasis Patients in Damazen Town the Blue Nile State Sudan
- 1Department of Microbiology, Faculty of Medicine and Health Sciences, University of Blue Nile, Sudan
- 2Departments of Biochemistry, Faculty of Medicine, University of Al-Butana , Sudan
- 3Departments of Microbiology and Parasitology, Faculty of Medicine and Health Sciences University of Dongola, Sudan
- 4Departments of Biochemistry, Faculty of Medicine and Health Sciences University of Blue Nile, Sudan
Int. Res. J. Medical Sci., Volume 7, Issue (1), Pages 7-9, January,28 (2019)
The aim of this study was to determine HIV-1 seropositivity among visceral leishmaniasis (VL) patients. It was also used to compare between ELISA, WB and RT-PCR as diagnostic test tools. The study was conducted on 200 patients and 200 healthy controls from Blue Nile State. We used Indirect Enzymatic-Link Immunosorbent Assay (ELISA), Western Blot Test and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) as diagnostic test. The HIV-1 seropositivity among the study groups were five individuals (2.5%) from patients group were positive for HIV-1 while, two (1.0%) of the healthy control were positive. The sensitivity and specificity of ELISA test, WB were 100% and 99.8% respectively, the diagnostic accuracy was 97.89%. Moreover, there was a complete agreement between ELISA and RT-PCR and WB results. In addition, there was no statistically significant difference between the two study groups regarding RT-PCR, WB and ELISA results (P>0.05). However there was no statistical significant difference between VL and HIV-1 (P>0.05). We concluded that ELISA was an adequate screening test for the diagnosis of HIV-1 with reasonable sensitivity and specificity. However, it should be confirmed by RT-PCR. RT-PCR was highly sensitive and specific test and was a gold standard test especially important when serological test was borderline. Moreover HIV-1 should be taken into consideration during the follow up of visceral leishmaniasis patients.
- Brooks G.F., Butel J.S. and Morse S.A. (1998)., Pathogenesis and control of viral diseases., Jawetz, Melnick, and Adelberg's medical microbiology, 21st ed. Appleton & Lange, Stamford, Conn, 363-365.
- Ryan K.J. and Ray C.G. (2004)., Sherris Medical Microbiology., 4th (ed). McGraw Hill, 749-754.
- Alvar Vanavate C., Guteirrez-Solar B., Jiminez M., Laguna F., Lopez-Velex R., Molina R. and Moreno I. (1997)., Leishmania and human immunodeficiency virus co-infection: The first 10 years., J of Clini Micro. Rev., 10(2), 298-319.
- Cruz I., Morales M.A., Noguer I., Rodriguez A. and Alvar J. (2002)., Leishmania in discarded syringes from intravenous drug users., The Lancet, 359(9312), 1124-1125.
- Desjeux P. (1995)., Leishmania/HIV co-infections., J Afr. Health., 18(1), 20-22.
- Kolaczinski J.H., Worku D.T., Chappuis F., Reithinger R., Kabatereine N., Onapa A. and Brooker S. (2007)., Kala-azar control, Uganda., Emerging infectious diseases, 13(3), 507.
- Dereure J., El-Safi S.H., Bucheton B., Boni M., Kheir M.M., Davoust B. and Dedet J. P. (2003)., Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships., Microbes and infection, 5(12), 1103-1108.
- Schupbach J., Doni J., Tomasik Z., Jendis J., Seger R., Kind C. and Swiss Neonatal DIV Study Group (1994)., Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants., Journal of Infectious Diseases, 170(2), 318-324.
- Levinson W. and Jawetz E. (2000)., Medical Microbiology and Immunology., 7th (ed) McGrawHill, New York, 286-294.
- Desjeux P. and Alrar J. (2003)., Leishmania / HIV co-infections: epidemiology in Europe., J of Annals Trop Med and Parasit., 97(1), 3-15.
- Ryan J.R., Smithyman A.M., Rajasekariah G.H., Hochberg L., Stiteler J.M. and Martin S.K. (2002)., Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis., Journal of clinical microbiology, 40(3), 1037-1043.
- Convit J., Rondon A., Ulrich M., Bloom B., Castellanos P., Pinardi M. and Garcia L. (1987)., Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis., The Lancet, 329(8530), 401-405.
- Wolday D., Akuffo H., Fessahaye G., Valantine A. and Britton S. (1998)., Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells., Scandinavian journal of infectious diseases, 30(1), 29-34.
- El-Safi S.H., Hamid N. and Omer A. (2002)., Infection rates with leishmania donovani and mycobacterium tuberculosis in a village in eastern Sudan., J of Microbes and infection, 4(1), 1439-1447.
- Tonui W.K. (1999)., Leishmania transmission-blocking vaccines: a review., East Africa Med. J., 76(2), 93-96.
- World Health Organization (2004)., The leishmaniasis and leishmania/HIV co-infection., WHO sites, 1-4.